Salmeterol inhalation powder - Boehringer Ingelheim

Drug Profile

Salmeterol inhalation powder - Boehringer Ingelheim

Alternative Names: Salmeterol xinafoate inhalation powder - Boehringer Ingelheim

Latest Information Update: 04 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 24 Sep 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Germany (Inhalation) prior to September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top